Clover Health Investments, Corp.
NASDAQ:CLOVMedical - Healthcare Plans
+$0.17 today
- Market cap
- $2.21B
- Beta
- 2.48
- P/E (TTM)
- -45.6
- EPS (TTM)
- -$0.11
Volume 8.05M
Average 7.31M
CLOV Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Clover Health Investments, Corp.NASDAQ: CLOV
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income turns positive
Q2 FY2026 net income was $28M, compared with -$10.58M a year earlier. Trailing-twelve-month net income was -$18.36M. Over 3 fiscal years it compounded at -36.8% a year.
Context
- Net income amounted to 4.4% of revenue in FY2025, up 1.3 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of $31.01M (+136.2%) for the fiscal year ending Dec 2026, a step up from the +98.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $28M+2.4% QoQ
- Last fiscal yearDec 2025
- -$85.55M+98.9% YoY
- LTMJun 2026
- -$18.36M-57.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +364.7% | -88.4% | -453.1 pp |
| 1 year | +98.9% | +136.2% | +37.3 pp |
| 3-year CAGR | -36.8% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (85.55M) USD
- Year-over-year change
- -98.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (85.55M) | -98.9% |
| FY2024 | 2024-12-31 | (43.01M) | +79.8% |
| FY2023 | 2023-12-31 | (213.36M) | +37.2% |
| FY2022 | 2022-12-31 | (339.57M) | +42.2% |
| FY2021 | 2021-12-31 | (587.76M) | — |
Net Income vs competitors
How CLOV compares with its peers on the latest reported figures
- CLOV's LTM Jun 2026 net income of $18.36M is the smallest of the 7 companies compared; the peer median is $896.47M.
- Its year-over-year change of -57.4% is the 6th highest of 7, against a peer median of +19.0%.
- Net income amounts to 0.7% of revenue for CLOV, versus a peer median of 1.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $6.71B | +2.4% | -2.5% | 2.3% | |
| LTM Jun 2026 | $6.1B | +35.6% | -26.4% | 1.5% | |
| LTM Jun 2026 | $5.11B | -350.3% | — | 2.6% | |
| LTM Sep 2026 | $1.24B | -3.9% | -24.6% | 0.8% | |
| LTM Jun 2026 | $550.93M | +443.4% | -10.1% | 3.6% | |
| LTM Mar 2026 | $19.79M | +121.8% | -83.1% | 0.5% | |
| LTM Jun 2026 | $18.36M | -57.4% | -36.8% | 0.7% | |
| Peer median (excluding CLOV) | $896.47M | +19.0% | -24.6% | 1.9% | |
Competitors are the stored peer set for CLOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (587.76M) | (339.57M) | (213.36M) | (43.01M) | (85.55M) |
| Depreciation & Amortization | 1.25M | 1.19M | 2.51M | 1.33M | 1.69M |
| Deferred Income Tax | (66.09M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 163.72M | 164.31M | 140.93M | 114.33M | 103.66M |
| Change in Working Capital | 192.67M | (2.36M) | (55.43M) | 12.86M | (84.2M) |
| Accounts Receivables | (9.39M) | (8.03M) | 0 | (6.55M) | (65.95M) |
| Inventory | 9.39M | 0 | 0 | 0 | 0 |
| Accounts Payables | 5.31M | 7.64M | 4.74M | (2.62M) | 1.65M |
| Other Working Capital | 187.37M | (1.97M) | (60.17M) | 22.03M | (19.9M) |
| Other Non-Cash Items | 13.88M | (27.49M) | 9.48M | (50.66M) | (2.53M) |
| Operating Cash Flow | (282.33M) | (203.93M) | (115.87M) | 34.85M | (66.93M) |
| Capital Expenditures | (723K) | (4.47M) | (584K) | (1.56M) | (2.04M) |
| Acquisitions (Net) | 434.72M | (16.2M) | 0 | 0 | 0 |
| Purchases of Investments | (876.25M) | (369.65M) | (175.57M) | (201.24M) | (205.1M) |
| Sales of Investments | 441.53M | 485.45M | 316.16M | 203.36M | 211.22M |
| Other Investing Activities | (434.72M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (435.45M) | 95.13M | 140.01M | 565K | 4.08M |
| Debt Repayment | (30.93M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 289.92M | 1.4M | 1.15M | 902K | 1.81M |
| Common Stock Repurchased | (147K) | (6.36M) | (6.22M) | (18.26M) | (55.2M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 666.55M | 0 | (28.79M) | 0 | 0 |
| Financing Cash Flow | 925.39M | (4.96M) | (33.86M) | (17.36M) | (53.38M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 207.62M | (113.76M) | (9.72M) | 18.05M | (116.24M) |
| Free Cash Flow | (283.05M) | (208.39M) | (116.46M) | 33.29M | (68.98M) |
Clover Health Investments, Corp.
NASDAQ:CLOV
Intrinsic Alpha fair value
Locked
Current Price
$4.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.